Patents by Inventor RAUL BLASCO

RAUL BLASCO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GPBP inhibition using Qpeptidomimetics
    Patent number: 10544083
    Abstract: Disclosed are compounds of formula: that inhibiting GPBP activity, making them useful as therapeutics in antibody-mediated disorders, drug-resistant cancer, inflammation, protein misfolding and ER stress-mediated disorders, and aberrant apoptosis.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: January 28, 2020
    Assignee: Universitat de València
    Inventors: Juan Saus, Santos Fustero, Juan F. Sanz-Cervera, Enrique Pérez-Payá, Raül Blasco, Francisco Revert-Ros, Fernando Revert
  • GPBP inhibition using Q2 peptidomimetics
    Publication number: 20180179139
    Abstract: Disclosed are compounds of formula: that inhibiting GPBP activity, making them useful as therapeutics in antibody-mediated disorders, drug-resistant cancer, inflammation, protein misfolding and ER stress-mediated disorders, and aberrant apoptosis.
    Type: Application
    Filed: February 8, 2018
    Publication date: June 28, 2018
    Inventors: Juan Saus, Santos Fustero, Juan F. Sanz-Cervera, Enrique Pérez-Payá, Raül Blasco, Francisco Revert-Ros, Fernando Revert
  • Methods for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition
    Publication number: 20160184274
    Abstract: Methods of using inhibitors of Goodpasture Antigen Binding Protein for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition (EMT), treating an invasive tumor, and detecting EMT in a tissue are described.
    Type: Application
    Filed: December 30, 2015
    Publication date: June 30, 2016
    Inventors: Juan Saus, Fernando Revert, Aida Artigot, Francisco Revert-Ros, Ernesto Lopez-Pascual, Raul Blasco, Nuria Roda, Juan F. Sanz-Cervera, Roberto Gozalbo-Rovira
  • GPBP inhibition using Q2 peptidomimetics
    Publication number: 20160083327
    Abstract: Disclosed are compounds of formula: that inhibiting GPBP activity, making them useful as therapeutics in antibody-mediated disorders, drug-resistant cancer, inflammation, protein misfolding and ER stress-mediated disorders, and aberrant apoptosis.
    Type: Application
    Filed: November 18, 2015
    Publication date: March 24, 2016
    Inventors: Juan Saus, Santos Fustero, Juan F. Sanz-Cervera, Enrique Pérez-Payá, Raül Blasco, Francisco Revert-Ros, Fernando Revert
  • GPBP inhibition using Q2 peptidomimetics
    Patent number: 9199936
    Abstract: Disclosed are compounds of formula: that inhibiting GPBP activity, making them useful as therapeutics in antibody-mediated disorders, drug-resistant cancer, inflammation, protein misfolding and ER stress-mediated disorders, and aberrant apoptosis.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: December 1, 2015
    Assignee: Fibrostatin Sociedad Limitada
    Inventors: Juan Saus, Santos Fustero, Juan F Sanz-Cervera, Enrique Pérez-Payá, Raül Blasco, Francisco Revert-Ros, Fernando Revert
  • GPBP-1 inhibition and its therapeutic use
    Publication number: 20150320730
    Abstract: The present invention provides compositions including anti-tumor agents and inhibitors of Goodpasture antigen binding protein, p21, and ABCC7, and their use in treating cancer.
    Type: Application
    Filed: June 17, 2015
    Publication date: November 12, 2015
    Inventors: Juan Saus, Francisco Ravert-Ros, Fernando Revert, Carmen Aguado-Velasco, Ernesto Lopez-Pascual, Alejandra Maria Perez-Sastre, Raúl Blasco, Héctor Pérez-Montoyo
  • GPBP-1 inhibition and its therapeutic use
    Patent number: 9066938
    Abstract: The present invention provides compositions including anti-tumor agents and inhibitors of Goodpasture antigen binding protein, p21, and ABCC7, and their use in treating cancer.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: June 30, 2015
    Assignees: Fibrostein, S.L., Universitat de Valencia
    Inventors: Juan Saus, Francisco Revert-Ros, Fernando Revert, Carmen Aguado-Velasco, Ernesto López-Pascual, Alejandra María Pérez-Sastre, Raúl Blasco, Héctor Pérez-Montoyo
  • GPBP inhibition using Q2 peptidomimetics
    Publication number: 20140080852
    Abstract: Disclosed are compounds of formula: that inhibiting GPBP activity, making them useful as therapeutics in antibody-mediated disorders, drug-resistant cancer, inflammation, protein misfolding and ER stress-mediated disorders, and aberrant apoptosis.
    Type: Application
    Filed: October 25, 2013
    Publication date: March 20, 2014
    Applicant: FIBROSTATIN, S.L.
    Inventors: Juan Saus, Santos Fustero, Juan F Sanz-Cervera, Enrique Pérez-Payá, Raül Blasco, Francisco Revert-Ros, Fernando Revert
  • GPBP-1 inhibition and its therapeutic use
    Publication number: 20140005134
    Abstract: The present invention provides compositions including anti-tumor agents and inhibitors of Goodpasture antigen binding protein, p21, and ABCC7, and their use in treating cancer.
    Type: Application
    Filed: July 2, 2013
    Publication date: January 2, 2014
    Inventors: Juan Saus, Francisco Revert-Ros, Fernando Revert, Carmen Aguado-Velasco, Ernesto López-Pascual, Alejandra Maria Pérez-Sastre, Raúl Blasco, Héctor Pérez-Montoyo
  • GPBP inhibition using Qpeptidomimetics
    Patent number: 8586776
    Abstract: Disclosed are compounds of formula: that inhibiting GPBP activity, making them useful as therapeutics in antibody-mediated disorders, drug-resistant cancer, inflammation, protein misfolding and ER stress-mediated disorders, and aberrant apoptosis.
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: November 19, 2013
    Assignee: FibroStatin, S.L.
    Inventors: Juan Saus, Santos Fustero, Juan F. Sanz-Cervera, Enrique Perez-Paya, Raul Blasco, Francisco Revert-Ros, Fernando Revert
  • GPBP inhibition using Q2 peptidomimetics
    Publication number: 20110105545
    Abstract: Disclosed are compounds of formula: that inhibiting GPBP activity, making them useful as therapeutics in antibody-mediated disorders, drug-resistant cancer, inflammation, protein misfolding and ER stress-mediated disorders, and aberrant apoptosis.
    Type: Application
    Filed: November 5, 2010
    Publication date: May 5, 2011
    Applicant: FIBROSTATIN, S.L.
    Inventors: JUAN SAUS, SANTOS FUSTERO, JUAN F. SANZ-CERVERA, ENRIQUE PEREZ-PAYA, RAUL BLASCO, FRANCISCO REVERT-ROS, FERNANDO REVERT